This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synta Announces Presentation Of Ganetespib Results At The 2013 European Cancer Congress

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of results from the GALAXY-1 trial, a global, randomized, multi-center Phase 2b/3 study designed to identify the patients with advanced non-small cell lung adenocarcinoma most likely to benefit from second-line treatment with the Company’s lead drug candidate, the Hsp90 inhibitor ganetespib. The results, from a planned interim analysis conducted in May, will be presented at the 2013 ECCO/ESMO/ESTRO conference and include a review of interim findings previously presented at ASCO 2013 as well as additional results for two of the study’s prespecified primary patient populations.

“We are encouraged by the improvements in PFS and OS in patients treated with ganetespib in the GALAXY-1 study,” said Dr. Vojo Vukovic, Chief Medical Officer, Synta. “We look forward to the GALAXY-1 final analysis, expected to be conducted later this year, and to results from GALAXY-2, expected in 2014.”

GALAXY program trial design

Drugs targeting the Hsp90 chaperone protein silence a broad network of cancer-promoting proteins, creating a wide range of potential biomarkers for selecting patients. The GALAXY-1 trial was designed to enroll a substantially larger number of patients than conventional Phase 2b trials, in order to allow sufficient statistical power to detect signals in one or more patient populations identified by Hsp90-related clinical markers.

Patients with non-small cell lung adenocarcinoma who had received one prior regimen for advanced disease were randomized 1:1 to treatment with either ganetespib plus docetaxel or docetaxel alone. Key patient populations evaluated include:

1. Patients with elevated LDH. LDH-A is a marker of HIF-1alpha activity, a strong Hsp90 client and a key driver of tumor invasiveness and metastasis. Ganetespib has been shown to inhibit HIF-1alpha in tumors in both preclinical models of cancer and in translational studies in patients.

Patients with elevated LDH have poor prognosis and limited treatment options, representing a population with high unmet medical need.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs